Research Articles (Journals)

2024

• zu Vilsendorf, Imke Meyer, Einerhand, Judith, Mulac, Dennis, Langer, Klaus, and Lehr, Matthias. 2024. “1-Benzylindoles as inhibitors of cytosolic phospholipase A2α: synthesis, biological activity, aqueous solubility, and cell permeability.” RSC Medicinal Chemistry, № 15 (2): 641. doi: 10.1039/d3md00590a.
• Adick, Annika, Hoheisel, Werner, Schneid, Stefan, Hester, Sarah, and Langer, Klaus. 2024. “Development of a screening platform for the formulation of poorly water-soluble drugs as albumin-stabilized nanosuspensions using nabTM technology.” International Journal of Pharmaceutics, № 662: 124491. doi: 10.1016/j.ijpharm.2024.124491.
• Tran, Xenia, Mulac, Dennis, and Langer, Klaus. 2024. “Investigating the selectivity of the targeting properties of trastuzumab-bound nanoparticles to HER2/neu positive cells in co-culture.” Journal of Drug Delivery Science and Technology, № 100: 106040. doi: 10.1016/j.jddst.2024.106040.
• Völlmecke, Katharina, Kramer, Maurice, Horky, Corinna, Dueckmann, Oliver, Mulac, Dennis, Langer, Klaus, and Kuckling, Dirk. 2024. “Self-immolative polydisulfides and their use as nanoparticles for drug delivery systems.” RSC Advances, № 14 (48): 35568. doi: 10.1039/d4ra07228f.

2023

• Subeska, A, Voundi, ME, Hanekamp, W, Mulac, D, Langer, K, and Lehr, M. 2023. “Synthesis, activity, metabolic stability and cell permeability of new cytosolic phospholipase A2α inhibitors with 1-indolyl-3-phenoxypropan-2-one structure.” Bioorganic and Medicinal Chemistry Letters, № 92: 129374–129374. doi: 10.1016/j.bmcl.2023.129374.
• Hardebeck, Sarah, Schreiber, Sebastian, Adick, Annika, Langer, Klaus, and Jose, Joachim. 2023. “A FRET-Based Assay for the Identification of PCNA Inhibitors.” International Journal of Molecular Sciences (IJMS), № 24 doi: 10.3390/ijms241411858.
• Adick, A., Hoheisel, W., Schneid, S., Mulac, D., Azhdari, S., and Langer, K. 2023. “Challenges of nanoparticle albumin bound (nab™) technology: Comparative study of Abraxane® with a newly developed albumin-stabilized itraconazole nanosuspension.” European journal of pharmaceutics and biopharmaceutics, № 193: 129–143. doi: 10.1016/j.ejpb.2023.10.022.
• Weitzel, J., Wünsch, A., Erzkamp, S., Rose, O., and Langer, K. 2023. “Problems with the change in generics: Justified complaints or only imagination of the patients? Probleme beim Generikawechsel Berechtigte Klagen oder nur Einbildung der Patienten?” Deutsche Apotheker-Zeitung, № 163 (2)
• Hester, S., B., Ferenz K., Adick, A., Kakalias, C., Mulac, D., Azhdari, S., and Langer, K. 2023. “Triglyceride-filled albumin-based nanocapsules: A promising new system to avoid discarding poorly water-soluble drug candidates.” International Journal of Pharmaceutics, № 646 doi: 10.1016/j.ijpharm.2023.123454.
• Feldmann, Anja, Nitschke, Yvonne, Linss, Franziska, Mulac, Dennis, Stuecker, Sina, Bertrand, Jessica, Buers, Insa, Langer, Klaus, and Rutsch, Frank. 2023. “Improved Reversion of Calcifications in Porcine Aortic Heart Valves Using Elastin-Targeted Nanoparticles.” International Journal of Molecular Sciences (IJMS), № 24 (22) doi: 10.3390/ijms242216471.
• Subeska, A, Althaus, J, Hake, T, Hanekamp, W, Bettenworth, D, Mulac, D, Langer, K, and Lehr, M. 2023. “Synthesis and pharmacokinetic properties of novel cPLA2α inhibitors with 1-(carboxyalkylpyrrolyl)-3-aryloxypropan-2-one structure.” Bioorganic & Medicinal Chemistry, № 77: 117110–117110. doi: 10.1016/j.bmc.2022.117110.

2022

• Hahn, M, Lindemann, V, Behrens, M, Mulac, D, Langer, K, Esselen, M, and Humpf, HU. 2022. “Permeability of dopamine D2 receptor agonist hordenine across the intestinal and blood-brain barrier in vitro.” PloS one, № 17 (6): e0269486–e0269486. doi: 10.1371/journal.pone.0269486.
• Weitzel, J, Wünsch, A, Rose, O, and Langer, K. 2022. “Different dissolution conditions affect stability and dissolution profiles of bioequivalent levodopa-containing oral dosage forms.” International Journal of Pharmaceutics, № 629: 122401–122401. doi: 10.1016/j.ijpharm.2022.122401.
• Barth, C., Spreen, H., Mulac, D., Keuter, L., Behrens, M., Humpf, H.-U., and Langer, K. 2022. “Spacer length and serum protein adsorption affect active targeting of trastuzumab-modified nanoparticles.” Biomaterials and Biosystems, № 5: 100032. doi: 10.1016/j.bbiosy.2021.100032.
• Barth, M., Rudolph, S., Kampschulze, J., Meyer zu Vilsendorf, I., Hanekamp, W., Mulac, D., Langer, K., and Lehr, M. 2022. “Hexafluoroisopropyl carbamates as selective MAGL and dual MAGL/FAAH inhibitors: Biochemical and physicochemical properties.” ChemMedChem, № 17: e2021007. doi: 10.1002/cmdc.202100757.
• Weitzel, Johanna, Langer, Klaus, and Rose, Olaf. 2022. “Effects of Generic Exchange of Levodopa Medication in Patients With Parkinson Disease.” Journal of Patient Safety, № 18 (7) doi: 10.1097/PTS.0000000000001015.
• Rust, Tarik, Jung, Dimitri, Langer, Klaus, and Kuckling, Dirk. 2022. “Stimuli-accelerated polymeric drug delivery systems.” Polymer International, № 72 (1) doi: 10.1002/pi.6474.
• Spreen, Hendrik, Barth, Christina, Keuter, Lucas, Mulac, Dennis, Humpf, Hans-Ulrich, and Langer, Klaus. 2022. “Tuning the protein corona of PLGA nanoparticles: Characterization of trastuzumab adsorption behavior and its cellular interaction with breast cancer cell lines.” Journal of Drug Delivery Science and Technology, № 74 doi: 10.1016/j.jddst.2022.103543.

2021

• Wünsch, A., Mulac, D., and Langer, K. 2021. “Lecithin coating as universal stabilization and functionalization strategy for nanosized drug carriers to overcome the blood-brain barrier.” Int. J. Pharm., № 593: 120146.
• Rust, T., Jung, D., Hoppe, A., Schoppa, T., Langer, K., and Kuckling, D. 2021. “Backbone-degradable (co-)polymers for light-triggered drug delivery.” ACS Appl. Polym. Mater., № 2021: 3831–3842.
• Jung, D., Rust, T., Völlmecke, K., Schoppa, T., Langer, K., and Kuckling, D. 2021. “Backbone vs. side-chain: Two light-degradable polyurethanes based on 6-nitropiperonal.” Polymer Chemistry, № 12: 4565–4575. doi: 10.1039/d1py00442e.
• Hester, S., Ferenz, K.B., Eitner, S., and Langer, K. 2021. “Development of a lyophilization process for long term storage of albumin based perfluorodecalin filled artificial oxygen carriers.” Pharmaceutics, № 13: 584.
• K., Langer. 2021. “mRNA- und DNA-Impfstoffe – Nanotechnologie der Covid-19-Vakzinen.” Pharm. Ztg., № 166: 1024–1031.
• Schoppa, T., Jung, D., Rust, T., Mulac, D., Kuckling, D., and Langer, K. 2021. “Light-responsive nanoparticles based on a novel nitropiperonal derived polyester as drug delivery systems for photosensitizers in PDT.” Int. J. Pharm., № 597: 120326.
• Spreen, H., Behrens, M., Mulac, D., Humpf, H., and Langer, K. 2021. “Identification of main influencing factors on the protein corona composition of PLGA and PLA nanoparticles.” European journal of pharmaceutics and biopharmaceutics, № 163: 212–222.

2020

• K., Langer. 2020. “Adjuvanzien im Europäischen Arzneibuch – Adjuvants in the European Pharmacopoeia.” Pharmakon, № 8: 351–356.
• Wünsch, A., Mulac, D., and Langer, K. 2020. “Lipoprotein imitating nanoparticles: Lecithin coating binds ApoE and mediates non-lysosomal uptake leading to transcytosis over the blood-brain barrier.” Int. J. Pharm., № 589: 119821.
• Mecate-Zambrano, A., Sukumar, S., Seebohm, G., Ciminski, K., Schreiber, A., Anhlan, D., Greune, L., Wixler, L., Grothe, S., Stein, N.C., Schmidt, M.A., Langer, K., Schwemmle, M., Shi, T., Ludwig, S., and Boergeling, Y. 2020. “Discrete spatio-temporal regulation of tyrosine phosphorylation directs influenza A virus M1 protein towards its function in virion assembly.” PLoS Pathogenes, № 16: e1008775.
• Sahnen, F., Kamps, J.P., and Langer, K. 2020. “Conversion of indomethacin nanosuspensions into solid dosage forms via fluid bed granulation and compaction.” Eur. J. Pharm. Biopharm., № 154: 89–97.
• Weitzel, J., Langer, K., Erzkamp, S., and Rose, O. 2020. “Effects of generic exchange of solid oral dosage forms in neurological disorders: A systematic review.” Int. J. Clin. Pharm., № 42: 393–417.
• Keuth, J., Nitschke, Y., Mulac, D., Riehemann, K., Rutsch, F., and Langer, K. 2020. “Reversion of arterial calcification by elastin-targeted DTPA-HSA nanoparticles.” Eur. J. Pharm. Biopharm., № 150: 108–119.

2019

• Pieper, S., Onafuye, H., Mulac, D., Cinatl, J., Wass, M.N.Michaelis M., and Langer, K. 2019. “Incorporation of doxorubicin in different polymer nanoparticles and their anti-cancer activity.” Beilstein J. Nanotechnol., № 10: 2062–2072.
• Onafuye, H., Pieper, S., Mulac, D., Cinatl, jr. J., Wass, M.N., Langer, K., and Michaelis, M. 2019. “Doxorubicin-loaded human serum albumin nanoparticles overcome transporter-mediated drug resistance.” Beilstein J. Nanotechnol., № 10: 1707–1715.
• Sun, J., Jung, D., Schoppa, T., Anderski, J., Picker, M.-T., Ren, Y., Mulac, D., Stein, N., Langer, K., and Kuckling, D. 2019. “Light-responsive serinol-based poylcarbonate and polyester as degradable scaffolds.” ACS Applied Bio Materials, № 2: 3038–3051.
• Kimani, N.M., Backhaus, S., Matasyoh, J.C., Kaiser, M., Herrmann, F.C., Schmidt, T.J., and Langer, K. 2019. “Preparation of sesquiterpene lactone loaded - PLA nanoparticles and evaluation of their antitrypanosomal activity.” Molecules, № 24: 2110.
• Partikel, K., Korte, R., Stein, N.C., Mulac, D., Herrmann, F.C., Humpf, H.-U., and Langer, K. 2019. “Effect of nanoparticle size and PEGylation on the protein corona of PLGA nanoparticles.” Eur. J. Pharm. Biopharm., № 2019: 70–80.
• Mahlert, L., Anderski, J., Schoppa, T., Mulac, D., Sun, J., Kuckling, D., and Langer, K. 2019. “In vitro evaluation of innovative light-responsive nanoparticles for controlled drug release in intestinal PDT.” Int. J. Pharm., № 565: 199–208.
• Partikel, K., Korte, R., Mulac, D., Humpf, H.-U., and Langer, K. 2019. “Serum type and concentration both affecting the protein corona composition of PLGA nanoparticles.” Beilstein J. Nanotechnol., № 10: 1002–1015.
• Mahlert, L., Anderski, J., Mulac, D., and Langer, K. 2019. “The impact of gastrointestinal mucus – new in vitro evaluation of promising mucus-penetrating PLGA-NP for photodynamic therapy in treatment of intestinal cancer.” Eur. J. Pharm. Sci., № 133: 28–39.
• Sun, J., Anderski, J., Picker, M.-T.Langer K., and Kuckling, D. 2019. “Preparation of light-responsive aliphatic polycarbonate via versatile polycondensation for controlled degradation.” Macromol. Chem. Phys., № 220: 1800539.
• Anderski, J., Mahlert, L., Sun, J., Birnbaum, W., Mulac, D., Schreiber, S., Herrmann, F., Kuckling, D., and Langer, K. 2019. “Light-responsive nanoparticles based on new polycarbonates as innovative drug delivery systems for photosensitizers in PDT.” International Journal of Pharmaceutics, № 557: 182–191.

2018

• Franz, J., Grünebaum, J., Schäfer, M., Mulac, D., Rehfeldt, F., Langer, K., Kramer, A., and Riethmüller, C. 2018. “Rhombic organization of microvilli domains found in a cell model of the human intestine.” PloS one, № 13 (1) doi: 10.1371/journal.pone.0189970.
• Gossmann, R., Spek, S., Langer, K., and Mulac, D. 2018. “Didodecyldimethylammonium bromide (DMAB) stabilized poly(lactic-co-glycolic acid) (PLGA) nanoparticles: Uptake and cytotoxic potential in Caco-2 cells.” Journal of Drug Delivery Science and Technology, № 43 (null): 430–438. doi: 10.1016/j.jddst.2017.11.002.
• Raudszus, B., Mulac, D., and Langer, K. 2018. “A new preparation strategy for surface modified PLA nanoparticles to enhance uptake by endothelial cells.” International Journal of Pharmaceutics, № 536 (1): 211–221. doi: 10.1016/j.ijpharm.2017.11.047.
• Horster, L., Bernhardt, A., Kiehm, K., and Langer, K. 2018. “Conversion of PLGA nanoparticle suspensions into solid dosage forms via fluid bed granulation and tableting.” European Journal Pharmaceutics Biopharmaceutics, № 134: 77–87.
• Sun, J., Birnbaum, W., Anderski, J., Picker, M.-T., Mulac, D., Langer, K., and Kuckling, D. 2018. “Use of light-degradable aliphatic polycarbonate nanoparticles as drug carrier for photosensitizer.” Biomacromolecules, № 19: 4677–4690.
• Anderski, J., Mahlert, L., Mulac, D., and Langer, K. 2018. “Mucus-penetrating nanoparticles: Promising drug delivery systems for the photodynamic therapy of intestinal cancer.” European journal of pharmaceutics and biopharmaceutics, № 129: 1–9.

2017

• Mesken, J., Iltsche, A., Mulac, D., and Langer, K. 2017. “Modifying plasmid-loaded HSA-nanoparticles with cell penetrating peptides −cellular uptake and enhanced gene delivery.” International Journal of Pharmaceutics, № 522: 198–209. doi: 10.1016/j.ijpharm.2017.03.006.
• Lappe, S., Mulac, D., and Langer, K. 2017. “Polymeric nanoparticles – Influence of the glass transition temperature on drug release.” International Journal of Pharmaceutics, № 517 (null): 338–347. doi: 10.1016/j.ijpharm.2016.12.025.

2016

• Niehoff, A., Grünebaum, J., Moosmann, A., Mulac, D., Söbbing, J., Niehaus, R., Buchholz, R., Kröger, S., Wiehe, A., Wagner, S., Sperling, M., von Briesen, H., Langer, K., and Karst, U. 2016. “Quantitative bioimaging of platinum group elements in tumor spheroids.” Analytica Chimica Acta, № 938 (null): 106–113. doi: 10.1016/j.aca.2016.07.021.
• Lüdeker, D., Gossmann, R., Langer, K., and Brunklaus, G. 2016. “Crystal Engineering of Pharmaceutical Co-crystals: "nMR Crystallography" of Niclosamide Co-crystals.” Crystal Growth and Design, № 16 (6): 3087–3100. doi: 10.1021/acs.cgd.5b01619.
• Gonnissen, D., Qu, Y., Langer, K., Öztürk, C., Zhao, Y., Chen, C., Seebohm, G., Düfer, M., Fuchs, H., Galla, H., and Riehemann, K. 2016. “Comparison of cellular effects of starch-coated SPIONs and poly(Lactic-co-glycolic acid) matrix nanoparticles on human monocytes.” International journal of nanomedicine, № 11 (null): 5221–5236. doi: 10.2147/IJN.S106540.
• John, C, Herz, T, Boos, J, Langer, K, and Hempel, G. 2016. “Asymmetrical flow field-flow fractionation for the analysis of PEG-asparaginase.” Talanta, № 146: 335–339. doi: 10.1016/j.talanta.2015.08.028.

2015

• Fahrländer, E., Schelhaas, S., Jacobs, A., and Langer, K. 2015. “PEGylated human serum albumin (HSA) nanoparticles: Preparation, characterization and quantification of the PEGylation extent.” Nanotechnology, № 26 (14): 145103. doi: 10.1088/0957-4484/26/14/145103.
• John, C., Herz, T., Boos, J., Langer, K., and Hempel, G. 2015. “A novel asymmetrical flow field-flow fractionation for the analysis of PEG asparaginase.” Talanta, № 146: 335–339.
• Look, J., Wilhelm, N., von Briesen, H., Noske, N., Günther, C., Langer, K., and Gorjup, E. 2015. “Ligand-modified human serum albumin nanoparticles for targeted gene delivery.” Mol. Pharm., № 12: 3202–3213.
• Grünebaum, J., Söbbing, J., Mulac, D., and Langer, K. 2015. “Nanoparticulate carriers for photodynamic therapy of cholangiocarcinoma: In vitro comparison of various polymer-based nanoparticles.” International Journal of Pharmaceutics, № 496 (2): 942–952. doi: 10.1016/j.ijpharm.2015.10.023.
• Afrimzon, E., Zurgil, N., Sobolev, M., Shafran, Y., Langer, K., Zlatev, I., Wronski, R., Windisch, M., von Briesen, H., Schmidt, R., Pietrzik, C., and Deutsch, M. 2015. “Detection and analysis of human serum albumin nanoparticles within phagocytic cells at the resolution of individual live cell or single 3D multicellular spheroid.” Journal of Nanoparticle Research, № 17 (12): 1–14. doi: 10.1007/s11051-015-3306-9.
• Gossmann, R., Langer, K., and Mulac, D. 2015. “New perspective in the formulation and characterization of didodecyldimethylammonium bromide (DMAB) stabilized poly(lactic-co-glycolic acid) (PLGA) nanoparticles.” PloS one, № 10 (7) doi: 10.1371/journal.pone.0127532.
• Spek, S., Häuser, M., Schäfer, M.M., and Langer, K. 2015. “Characterisation of PEGylated PLGA nanoparticles comparing the nanoparticle bulk to the particle surface using UV/Vis spectroscopy, SEC, 1H-NMR spectroscopy, and X-ray photoelectron spectroscopy.” Appl. Surf. Sci., № 347
• Michaelis, M., Agha, B., Rothweiler, F., Löschmann, N., Voges, Y., Mittelbronn, M., Starzetz, T., Harter, P.N., Abhari, B.A., Fulda, S., Westermann, F., Riecken, K., Spek, S., Langer, K., Wiese, M., Dirks, W.G., Zehner, R., Cinatl, J., Wass, M.N., and Cinatl, jr. J. 2015. “Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen.” Sci. Rep., № 5
• K., Langer. 2015. “2nd Pharm School Symposium: Networked study in Münster.” Pharmazeutische Zeitung, № 160 (6)
• Borgognoni, C., Mormann, M., Qu, Y., Schäfer, M., Langer, K., Öztürk, C., Wagner, S., Chen, C., Zhao, Y., Fuchs, H., and Riehemann, K. 2015. “Reaction of human macrophages on protein corona covered TiO2 nanoparticles.” Nanomedicine: Nanotechnology, Biology and Medicine, № 11 (2): 275–282. doi: 10.1016/j.nano.2014.10.001.
• Gossmann, R., Fahrländer, E., Hummel, M., Mulac, D., Brockmeyer, J., and Langer, K. 2015. “Comparative examination of adsorption of serum proteins on HSA- and PLGA-based nanoparticles using SDS-PAGE and LC-MS.” European journal of pharmaceutics and biopharmaceutics, № 93: 80–87. doi: 10.1016/j.ejpb.2015.03.021.
• Plöger, M, Sendker, J, Langer, K, and Schmidt, TJ. 2015. “Covalent modification of human serum albumin by the natural sesquiterpene lactone parthenolide.” Molecules, № 20: 6211–6223. doi: 10.3390/molecules20046211.

2014

• Martínez, Vera N.P., Schmidt, R., Langer, K., Zlatev, I., Wronski, R., Auer, E., Havas, D., Windisch, M., von Briesen, H., Wagner, S., Stab, J., Deutsch, M., Pietrzik, C., Fazekas, F., and Ropele, S. 2014. “Tracking of magnetite labeled nanoparticles in the rat brain using MRI.” PloS one, № 9 (3): e92068. doi: 10.1371/journal.pone.0092068.
• John, C., and Langer, K. 2014. “Asymmetrical flow field-flow fractionation for human serum albumin based nanoparticle characterisation and a deeper insight into particle formation processes.” Journal of Chromatography A, № 1346: 97–106. doi: 10.1016/j.chroma.2014.04.048.
• Niehoff, A.-C., Moosmann, A., Söbbing, J., Wiehe, A., Mulac, D., Wehe, C.A., Reifschneider, O., Blaske, F., Wagner, S., Sperling, M., von Briesen, H., Langer, K., and Karst, U. 2014. “A palladium label to monitor nanoparticle-assisted drug delivery of a photosensitizer into tumor spheroids by elemental bioimaging.” Metallomics, № 6 (1): 77–81. doi: 10.1039/c3mt00223c.
• Engel, A., Ploger, M., Mulac, D., and Langer, K. 2014. “Asymmetric flow field-flow fractionation (AF4) for the quantification of nanoparticle release from tablets during dissolution testing.” International Journal of Pharmaceutics, № 461 (1): 137–144. doi: 10.1016/j.ijpharm.2013.11.044.
• K., Langer. 2014. “Medicine-related problems in practice: Tablet splitting - (no) a problem? | Arzneimittelbezogene Probleme in der Praxis: Tablettenteilung - (k)ein Problem?” Pz Prisma, № 21 (2): 75–81.

2013

• Meister, S., Zlatev, I., Stab, J., Docter, D., Baches, S., Stauber, R.H., Deutsch, M., Schmidt, R., Ropele, S., Windisch, M., Langer, K., Wagner, S., Von Briesen, H., Weggen, S., and Pietrzik, C.U. 2013. “Nanoparticulate flurbiprofen reduces amyloid-β42 generation in an in vitro blood-brain barrier model.” Alzheimer's Research and Therapy, № 5 (6) doi: 10.1186/alzrt225.

2012

• Storp, B., Engel, A., Böker, A., Plöger, M., and Langer, K. 2012. “Albumin nanoparticles with predictable size by desolvation procedure.” Journal of Microencapsulation, № 29 (2): 138–46. doi: 10.3109/02652048.2011.635218.

2011

• Preuß, A., Chen, K., Hackbarth, S., Wacker, M., Langer, K., and Röder, B. 2011. “Photosensitizer loaded HSA nanoparticles II: In vitro investigations.” International Journal of Pharmaceutics, № 404 (1-2): 308–316. doi: 10.1016/j.ijpharm.2010.11.023.
• Löw, K., Knobloch, T., Wagner, S., Wiehe, A., Engel, A., Langer, K., and von Briesen, H. 2011. “Comparison of intracellular accumulation and cytotoxicity of free mTHPC and mTHPC-loaded PLGA nanoparticles in human colon carcinoma cells.” Nanotechnology, № 22 (24): 245102. doi: 10.1088/0957-4484/22/24/245102.
• Löw, K., Wacker, M., Wagner, S., Langer, K., and von Briesen, H. 2011. “Targeted human serum albumin nanoparticles for specific uptake in EGFR-Expressing colon carcinoma cells.” Nanomedicine: Nanotechnology, Biology and Medicine, № 7 doi: 10.1016/j.nano.2010.12.003.

2010

• Chen, K., Wacker, M., Hackbarth, S., Ludwig, C., Langer, K., and Röder, B. 2010. “Photophysical evaluation of mTHPC-loaded HSA nanoparticles as novel PDT delivery systems.” Journal of Photochemistry and Photobiology B: Biology, № 101 (3): 340–7. doi: 10.1016/j.jphotobiol.2010.08.006.
• Preuß, A., Hackbarth, S., Wacker, M., Knobloch, T., Langer, K., and Röder, B. 2010. “Comprehensive in vitro investigations on biodegradable photosensitizer-nanoparticle delivery systems.” Journal of Controlled Release, № 148 (1): e117–e118. doi: 10.1016/j.jconrel.2010.07.089.
• Preuß, A., Chen, K., Hackbarth, S., Wacker, M., Langer, K., and Röder, B. 2010. “Photosensitizer loaded HSA nanoparticles II: In vitro investigations.” International Journal of Pharmaceutics, № 404: 308–316. doi: 10.1016/j.ijpharm.2010.11.023.
• Wacker, M., Chen, K., Preuss, A., Possemeyer, K., Röder, B., and Langer, K. 2010. “Photosensitizer loaded HSA nanoparticles. I: Preparation and photophysical properties.” International Journal of Pharmaceutics, № 393 (1-2): 253–62. doi: 10.1016/j.ijpharm.2010.04.022.
• Wagner, S., Rothweiler, F., Anhorn, M.G., Sauer, D., Riemann, I., Weiss, E.C., Katsen-Globa, A., Michaelis, M., Cinatl, J., Schwartz, D., Kreuter, J., von Briesen, H., and Langer, K. 2010. “Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticles.” Biomaterials, № 31 (8): 2388–98. doi: 10.1016/j.biomaterials.2009.11.093.
• Geiler, J., Michaelis, M., Naczk, P., Leutz, A., Langer, K., Doerr, H.W., and Cinatl, J. 2010. “N-acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus.” Biochemical Pharmacology, № 79 (3): 413–420. doi: 10.1016/j.bcp.2009.08.025.

2009

• Steinhauser, I., Langer, K., Strebhardt, K., and Spänkuch, B. 2009. “Uptake of plasmid-loaded nanoparticles in breast cancer cells and effect on Plk1 expression.” Journal of Drug Targeting, № 17 (8): 627–37. doi: 10.1080/10611860903118823.
• Chen, K., Preuss, A., Hackbarth, S., Wacker, M., Langer, K., and Röder, B. 2009. “Novel photosensitizer-protein nanoparticles for photodynamic therapy: photophysical characterization and in vitro investigations.” Journal of Photochemistry and Photobiology B: Biology, № 96 (1): 66–74. doi: 10.1016/j.jphotobiol.2009.04.006.
• Holzer, M., Vogel, V., Mäntele, W., Schwartz, D., Haase, W., and Langer, K. 2009. “Physico-chemical characterisation of PLGA nanoparticles after freeze-drying and storage.” European journal of pharmaceutics and biopharmaceutics, № 72 (2): 428–37.
• Müller, R.S., and Langer, K. 2009. “Nanotechnologie: Nanopartikel bringen Arzneistoffe sicher ans Ziel.” Pharmazeutische Zeitung, № 4

2008

• Anhorn, M.G., Wagner, S., Kreuter, J., Langer, K., and von Briesen, H. 2008. “Specific Targeting of HER2 Overexpressing Breast Cancer Cells with Doxorubicin-Loaded Trastuzumab-Modified Human Serum Albumin Nanoparticles.” Bioconjugate Chemistry, № 19 (12): 2321–2331. doi: 10.1021/bc8002452.
• Anhorn, M.G., Mahler, H.C., and Langer, K. 2008. “Freeze drying of human serum albumin (HSA) nanoparticles with different excipients.” International Journal of Pharmaceutics, № 363 (1-2): 162–9. doi: 10.1016/j.ijpharm.2008.07.004.
• Steinhauser, I.M., Langer, K., Strebhardt, K.M., and Spänkuch, B. 2008. “Effect of trastuzumab-modified antisense oligonucleotide-loaded human serum albumin nanoparticles prepared by heat denaturation.” Biomaterials, № 29 (29): 4022–8. doi: 10.1016/j.biomaterials.2008.07.001.
• Michaelis, M., Bliss, J., Arnold, S.C., Hinsch, N., Rothweiler, F., Deubzer, H.E., Witt, O., Langer, K., Doerr, H.W., Wels, W.S., and Cinatl, J. 2008. “Cisplatin-Resistant Neuroblastoma Cells Express Enhanced Levels of Epidermal Growth Factor Receptor (EGFR) and Are Sensitive to Treatment with EGFR-Specific Toxins.” Clinical Cancer Research, № 14 (20): 6531–6537. doi: 10.1158/1078-0432.CCR-08-0821.
• Spänkuch, B., Steinhauser, I., Wartlick, H., Kurunci-Csacsko, E., Strebhardt, K.I., and Langer, K. 2008. “Downregulation of Plk1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles.” Neoplasia, № 10 (3): 223–34. doi: 10.1593/neo.07916.
• Langer, K., Anhorn, M.G., Steinhauser, I., Dreis, S., Celebi, D., Schrickel, N., Faust, S., and Vogel, V. 2008. “Human serum albumin (HSA) nanoparticles: reproducibility of preparation process and kinetics of enzymatic degradation.” International Journal of Pharmaceutics, № 347 (1-2): 109–17. doi: 10.1016/j.ijpharm.2007.06.028.

2007

• Dreis, S., Rothweiler, F., Michaelis, M., Cinatl, J., Kreuter, J., and Langer, K. 2007. “Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles.” International Journal of Pharmaceutics, № 341 (1-2): 207–14. doi: 10.1016/j.ijpharm.2007.03.036.
• Pereverzeva, E., Treschalin, I., Bodyagin, D., Maksimenko, O., Langer, K., Dreis, S., Asmussen, B., Kreuter, J., and Gelperina, S. 2007. “Influence of the formulation on the tolerance profile of nanoparticle-bound doxorubicin in healthy rats: focus on cardio- and testicular toxicity.” International Journal of Pharmaceutics, № 337 (1-2): 346–56. doi: 10.1016/j.ijpharm.2007.01.031.
• Kreuter, J., Hekmatara, T., Dreis, S., Vogel, T., Gelperina, S., and Langer, K. 2007. “Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain.” Journal of Controlled Release, № 118 (1): 54–8. doi: 10.1016/j.jconrel.2006.12.012.

2006

• Steinhauser, I., Spänkuch, B., Strebhardt, K., and Langer, K. 2006. “Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells.” Biomaterials, № 27 (28): 4975–83. doi: 10.1016/j.biomaterials.2006.05.016.
• Michaelis, K., Hoffmann, M.M., Dreis, S., Herbert, E., Alyautdin, R.N., Michaelis, M., Kreuter, J., and Langer, K. 2006. “Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain.” Journal of Pharmacology and Experimental Therapeutics, № 317 (3): 1246–53. doi: 10.1124/jpet.105.097139.

2005

• Dinauer, N., Balthasar, S., Weber, C., Kreuter, J., Langer, K., and von Briesen, H. 2005. “Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes.” Biomaterials, № 26 (29): 5898–906. doi: 10.1016/j.biomaterials.2005.02.038.
• Balthasar, S., Michaelis, K., Dinauer, N., von Briesen, H., Kreuter, J., and Langer, K. 2005. “Preparation and characterisation of antibody modified gelatin nanoparticles as drug carrier system for uptake in lymphocytes.” Biomaterials, № 26 (15): 2723–32. doi: 10.1016/j.biomaterials.2004.07.047.

2004

• Wartlick, H., Michaelis, K., Balthasar, S., Strebhardt, K., Kreuter, J., and Langer, K. 2004. “Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells.” Journal of Drug Targeting, № 12 (7): 461–71. doi: 10.1080/10611860400010697.
• Michaelis, M., Langer, K., Arnold, S., Doerr, H.W., Kreuter, J., and Cinatl, J. 2004. “Pharmacological activity of DTPA linked to protein-based drug carrier systems.” Biochemical and Biophysical Research Communications, № 323 (4): 1236–40. doi: 10.1016/j.bbrc.2004.08.223.
• Brzoska, M., Langer, K., Coester, C., Loitsch, S., Wagner, T.O., and Mallinckrodt, C. 2004. “Incorporation of biodegradable nanoparticles into human airway epithelium cells-in vitro study of the suitability as a vehicle for drug or gene delivery in pulmonary diseases.” Biochemical and Biophysical Research Communications, № 318 (2): 562–70. doi: 10.1016/j.bbrc.2004.04.067.
• Brzoska, M., Langer, K., Coester, C., Loitsch, S., Wagner, T.O.F., and Mallinckrodt, C.V. 2004. “Incorporation of biodegradable nanoparticles into human airway epithelium cells - in vitro study of the suitability as a vehicle for drug or gene delivery in pulmonary diseases.” Biochemical and Biophysical Research Communications, № 318 (2): 562–570. doi: 10.1016/j.bbrc.2004.04.067.
• Wartlick, H., Spänkuch-Schmitt, B., Strebhardt, K., Kreuter, J., and Langer, K. 2004. “Tumour cell delivery of antisense oligonuclceotides by human serum albumin nanoparticles.” Journal of Controlled Release, № 96 (3): 483–95. doi: 10.1016/j.jconrel.2004.01.029.
• Wartlick, H., Spänkuch-Schmitt, B., Strebhardt, K., Kreuter, J., and Langer, K. 2004. “Tumour cell delivery of antisense oligonucleotides by human serum albumin nanoparticles.” Journal of Controlled Release, № 96 (3): 483–495. doi: 10.1016/j.jconrel.2004.01.029.

2003

• Rhaese, S., von Briesen, H., Rübsamen-Waigmann, H., Kreuter, J., and Langer, K. 2003. “Human serum albumin-polyethylenimine nanoparticles for gene delivery.” Journal of Controlled Release, № 92 (1-2): 199–208.
• Langer, K., Balthasar, S., Vogel, V., Dinauer, N., von Briesen, H., and Schubert, D. 2003. “Optimization of the preparation process for human serum albumin (HSA) nanoparticles.” International Journal of Pharmaceutics, № 257 (1-2): 169–80. doi: 10.1016/S0378-5173(03)00134-0.

2002

• Michaelis, M., Langer, K., Vogel, J.U., Kreuter, J., Rabenau, H., Doerr, H.W., and Cinatl, J. 2002. “In vitro antiviral activity of aphidicolin and its derivates - Synergistic effects of aphidicolin with other antiviral drugs.” Arzneimittel-Forschung, № 52 (5): 393–399.
• Michaelis, M., Cinatl, J., Cinatl, J., Pouckova, P., Langer, K., Kreuter, J., and Matousek, J. 2002. “Coupling of the antitumoral enzyme bovine seminal ribonuclease to polyethylene glycol chains increases its systemic efficacy in mice.” Anti-Cancer Drugs, № 13 (2): 149–154. doi: 10.1097/00001813-200202000-00006.

2000

• Weber, C., Reiss, S., and Langer, K. 2000. “Preparation of surface modified protein nanoparticles by introduction of sulfhydryl groups.” International Journal of Pharmaceutics, № 211 (1-2): 67–78. doi: 10.1016/S0378-5173(00)00590-1.
• Michaelis, M., Vogel, J.U., Cinati, J., Langer, K., Kreuter, J., Schwabe, D., Driever, P.H., and Cinati, J. 2000. “Cytotoxicity of aphidicolin and its derivatives against neuroblastoma cells in vitro: synergism with doxorubicin and vincristine.” Anti-Cancer Drugs, № 11 (6): 479–485. doi: 10.1097/00001813-200007000-00009.
• Michaelis, M., Matousek, J., Vogel, J.U., Slavik, T., Langer, K., Cinatl, J., Kreuter, J., Schwabe, D., and Cinatl, J. 2000. “Bovine seminal ribonuclease attached to nanoparticles made of polylactic acid kills leukemia and lymphoma cell lines in vitro.” Anti-Cancer Drugs, № 11 (5): 369–76. doi: 10.1097/00001813-200006000-00007.
• Langer, K., Coester, C., Weber, C., von Briesen, H., and Kreuter, J. 2000. “Preparation of avidin-labeled protein nanoparticles as carriers for biotinylated peptide nucleic acid.” European journal of pharmaceutics and biopharmaceutics, № 49 (3): 303–7.
• Coester, C.J., Langer, K., von Briesen, H., and Kreuter, J. 2000. “Gelatin nanoparticles by two step desolvation--a new preparation method, surface modifications and cell uptake.” Journal of Microencapsulation, № 17 (2): 187–93. doi: 10.1080/026520400288427.
• Coester, C.J., Langer, K., von Briesen, H., and Kreuter, J. 2000. “Gelatin nanoparticles by two step desolvation - a new preparation method, surface modifications and cell uptake.” Journal of Microencapsulation, № 17 (2): 187–193.
• Weber, C., Kreuter, J., and Langer, K. 2000. “Desolvation process and surface characteristics of HSA-nanoparticles.” International Journal of Pharmaceutics, № 196 (2): 197–200. doi: 10.1016/S0378-5173(99)00420-2.
• Coester, C., Kreuter, J., von Briesen, H., and Langer, K. 2000. “Preparation of avidin-labelled gelatin nanoparticles as carriers for biotinylated peptide nucleic acid (PNA).” International Journal of Pharmaceutics, № 196 (2): 147–9. doi: 10.1016/S0378-5173(99)00409-3.
• Weber, C., Coester, C., Kreuter, J., and Langer, K. 2000. “Desolvation process and surface characterisation of protein nanoparticles.” International Journal of Pharmaceutics, № 194 (1): 91–102. doi: 10.1016/S0378-5173(99)00370-1.

1999

• Weber, C., Michaelis, M., Vogel, J.U., Cinatl, J., Kreuter, J., and Langer, K. 1999. “Simple and efficient method for the detection of diethylenetriaminepentaacetic acid.” Journal of Chromatography B, № 736 (1-2): 299–303. doi: 10.1016/S0378-4347(99)00456-9.

1998

• Aliautdin, R.N., Petrov, V.E., Langer, K., Berthold, A., Kreuter, J., and Kharkevich, D.A. 1998. “The delivery of loperamide to the brain by using polybutyl cyanoacrylate nanoparticles | Dostavka loperamida v mozg s pomoshch'iu polibutiltsianoarilatnykh nanochastits.” Eksperimental'naia i klinicheskaia farmakologiia, № 61 (1): 17–20.
• Aliautdin, R.N., Petrov, V.E., Langer, K., Berthold, A., Kreuter, J., and Kharkevich, D.A. 1998. “[The delivery of loperamide to the brain by using polybutyl cyanoacrylate nanoparticles].” Eksperimental'naia i klinicheskaia farmakologiia, № 61 (1): 17–20.

1997

• Langer, K., Zimmer, A., and Kreuter, J. 1997. “Acrylic nanoparticles for ocular drug delivery.” S.T.P. Pharma Sciences, № 7 (6): 445–451.
• Langer, K., Stieneker, F., Lambrecht, G., Mutschler, E., and Kreuter, J. 1997. “Methylmethacrylate sulfopropylmethacrylate copolymer nanoparticles for drug delivery. Part II: Arecaidine propargyl ester and pilocarpine loading and in vitro release.” International Journal of Pharmaceutics, № 158 (2): 211–217. doi: 10.1016/S0378-5173(97)00256-1.
• Langer, K., Mutschler, E., Lambrecht, G., Mayer, D., Troschau, G., Stieneker, F., and Kreuter, J. 1997. “Methylmethacrylate sulfopropylmethacrylate copolymer nanoparticles for drug delivery. Part III: Evaluation as drug delivery system for ophthalmic applications.” International Journal of Pharmaceutics, № 158 (2): 219–231. doi: 10.1016/S0378-5173(97)00255-X.
• Langer, K., Lambrecht, G., Moser, U., Mutschler, E., and Kreuter, J. 1997. “Quantitative colorimetric and gas chromatographic determination of arecaidine propargyl ester.” Journal of Chromatography B: Biomedical applications, № 692 (2): 345–350. doi: 10.1016/S0378-4347(96)00521-X.
• Alyautdin, R.N., Petrov, V.E., Langer, K., Berthold, A., Kharkevich, D.A., and Kreuter, J. 1997. “Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles.” Pharmaceutical Research, № 14 (3): 325–8. doi: 10.1023/A:1012098005098.

1996

• Pirker, S., Kruse, J., Noe, C., Langer, K., Zimmer, A., and Kreuter, J. 1996. “Characterization of polybutyleyanoacrylate nanoparticles. Part II: Determination of polymer content by NMR-analysis.” International Journal of Pharmaceutics, № 128 (1-2): 189–195. doi: 10.1016/0378-5173(95)04305-5.
• Langer, K., Marburger, C., Berthold, A., Kreuter, J., and Stieneker, F. 1996. “Methylmethacrylate sulfopropylmethacrylate copolymer nanoparticles for drug delivery. Part I: Preparation and physicochemical characterization.” International Journal of Pharmaceutics, № 137 (1): 67–74. doi: 10.1016/0378-5173(96)89589-5.

1994

• Langer, K., Seegmüller, E., Zimmer, A., and Kreuter, J. 1994. “Characterisation of polybutylcyanoacrylate nanoparticles: I. Quantification of PBCA polymer and dextrans.” International Journal of Pharmaceutics, № 110 (1): 21–27. doi: 10.1016/0378-5173(94)90371-9.

Research Article (Book Contributions)

2015

• K., Langer. 2015. “Überblick über Messmethoden und deren physikalische Hintergründe: Submikron.” in Partikel in der Pharmaproduktion, edited by Stieneker F..

2005

• K., Langer. 2005. “Peptide nanoparticles.” in Nanotechnologies for the Life Sciences, Vol. 2: Biological and Pharmaceutical Nanomaterials, edited by Kumar C..